SRR1797236
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.460
- HEDGEHOG_SIGNALING+0.320
- NOTCH_SIGNALING+0.240
- WNT_BETA_CATENIN_SIGNALING+0.240
- MYOGENESIS+0.200
- KRAS_SIGNALING_DN+0.190
- APICAL_JUNCTION+0.180
- HYPOXIA+0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.140
- ANGIOGENESIS+0.120
Top 10 suppressed
- E2F_TARGETS-0.330
- MYC_TARGETS_V1-0.310
- G2M_CHECKPOINT-0.290
- MYC_TARGETS_V2-0.270
- MITOTIC_SPINDLE-0.230
- DNA_REPAIR-0.220
- ALLOGRAFT_REJECTION-0.210
- IL6_JAK_STAT3_SIGNALING-0.170
- PROTEIN_SECRETION-0.140
- INTERFERON_ALPHA_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418837 | GTEX | — | 0.753 |
| 2 | SRR1405485 | GTEX | — | 0.748 |
| 3 | MDT-AP-1211 | Med | Medulloblastoma | 0.735 |
| 4 | MNG792 | — | — | 0.735 |
| 5 | SRR1421351 | GTEX | — | 0.735 |
| 6 | SRR1352975 | GTEX | — | 0.726 |
| 7 | SRR1337864 | GTEX | — | 0.722 |
| 8 | SRR1409305 | GTEX | — | 0.713 |
| 9 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.712 |
| 10 | SRR25617932 | — | A | 0.710 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |